Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BND020
MIFTS: 57

Bone Disease

Categories: Bone diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Disease

About this section

MalaCards integrated aliases for Bone Disease:

Name: Bone Disease 11 14 16 75
Bone Diseases 53 41 43 14 71
Disorder of Skeletal System 71
Skeletal Disorder 53
Skeletal Disease 11

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:0080001
MeSH 43 D001847
SNOMED-CT 68 76069003
ICD10 31 M89 M89.8 M89.9
UMLS 71 C0005940 C0263661
Sources

Summaries for Bone Disease

About this section

MedlinePlus: 41 Your bones help you move, give you shape and support your body. They are living tissues that rebuild constantly throughout your life. During childhood and your teens, your body adds new bone faster than it removes old bone. After about age 20, you can lose bone faster than you make bone. To have strong bones when you are young, and to prevent bone loss when you are older, you need to get enough calcium, vitamin D, and exercise. You should also avoid smoking and drinking too much alcohol. Bone diseases can make bones easy to break. Different kinds of bone problems include: Low bone density and osteoporosis, which make your bones weak and more likely to break Osteogenesis imperfecta makes your bones brittle Paget's disease of bone makes them weak Bones can also develop cancer and infections Other bone diseases, which are caused by poor nutrition, genetics, or problems with the rate of bone growth or rebuilding NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Bone Disease, also known as bone diseases, is related to brittle bone disorder and osteopetrosis, and has symptoms including back pain, bone pain and sciatica. An important gene associated with Bone Disease is DANCR (Differentiation Antagonizing Non-Protein Coding RNA), and among its related pathways/superpathways are Vitamin D receptor pathway and Endochondral ossification. The drugs Buprenorphine and Methadone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology: 11 A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function.

Wikipedia: 75 Bone disease refers to the medical conditions which affect the... more...
Sources

Related Diseases for Bone Disease

About this section

Diseases in the Bone Disease family:

Trpv4-Related Bone Disorder

Diseases related to Bone Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 902)
# Related Disease Score Top Affiliating Genes
1 brittle bone disorder 33.2 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
2 osteopetrosis 33.1 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 CTSK CALCA
3 gorham's disease 33.0 TNFSF11 PTH CALCA
4 paget's disease of bone 32.9 TNFSF11 TNFRSF11B TNFRSF11A PTH CTSK CALCA
5 ischemic bone disease 32.8 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
6 paget disease of bone 5, juvenile-onset 32.8 TNFSF11 TNFRSF11B TNFRSF11A CALCA
7 osteitis fibrosa 32.7 SOST PTH FGF23 CALCA BGLAP B2M
8 renal osteodystrophy 32.6 TNFSF11 TNFRSF11B PTH FGF23 CALCA BGLAP
9 chronic kidney disease 32.5 TNFSF11 TNFRSF11B SOST RUNX2 PTH FGF23
10 primary hyperparathyroidism 32.3 TNFSF11 SOST PTH FGF23 CD36 CALCA
11 osteonecrosis 32.3 TNFRSF11B RUNX2 PTH BGLAP ACP5
12 enchondromatosis, multiple, ollier type 32.2 TNFSF11 RUNX2 PTH FGFR3 EXT2 EXT1
13 myeloma, multiple 32.2 TNFSF11 TNFRSF11B TNFRSF11A FGFR3 DKK1 CD36
14 hyperparathyroidism 32.1 TNFSF11 TNFRSF11B SOST PTH FGF23 CALCA
15 hypophosphatasia 32.1 SOST RUNX2 PTH FGF23 BGLAP ALPP
16 arthropathy 32.1 TNFSF11 TNFRSF11B TNFRSF11A B2M ALPL
17 craniometaphyseal dysplasia, autosomal dominant 32.1 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 BGLAP
18 bone remodeling disease 32.1 TNFSF11 TNFRSF11A SOST RUNX2 PTH FGF23
19 cleidocranial dysplasia 1 32.1 TNFSF11 RUNX2 FGFR3 CTSK BGLAP ALPL
20 osteomalacia 32.1 TNFSF11 SOST PTH FGF23 CD36 CALCA
21 bone development disease 32.0 TNFSF11 SOST RUNX2 PTH FGFR3 CTSK
22 rickets 32.0 PTH FGF23 CD36 CALCA BGLAP ALPP
23 kohler's disease 31.9 PTH CALCA
24 bone structure disease 31.9 RUNX2 PTH BGLAP
25 cherubism 31.9 TNFSF11 FGFR3 CALCA
26 metachondromatosis 31.9 EXT2 EXT1 CTSK
27 hypophosphatasia, adult 31.9 PTH ALPL
28 kidney disease 31.8 TNFSF11 TNFRSF11B SOST RUNX2 PTH FGF23
29 secondary hyperparathyroidism 31.8 TNFRSF11B PTH FGF23 CALCA BGLAP B2M
30 osteoporosis 31.8 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
31 spondyloepiphyseal dysplasia with congenital joint dislocations 31.8 FGFR3 EXT2 EXT1
32 mammary paget's disease 31.7 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
33 hypophosphatasia, childhood 31.7 SOST ALPL
34 hypophosphatemia 31.4 SOST PTH FGF23 BGLAP
35 hyperphosphatemia 31.4 TNFRSF11B RUNX2 PTH FGF23 BGLAP
36 hypoparathyroidism 31.4 PTH FGF23 CALCA BGLAP ALPP
37 osteomyelitis 31.3 TNFSF11 TNFRSF11A CTSK CALCA ALPL ACP5
38 endosteal hyperostosis, autosomal dominant 31.3 TNFSF11 TNFRSF11B SOST PTH DKK1 CTSK
39 uremia 31.3 TNFRSF11B RUNX2 PTH FGF23 B2M
40 osteogenic sarcoma 31.2 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 PTH DANCR
41 osteoarthritis 31.1 TNFSF11 TNFRSF11B RUNX2 CTSK BGLAP
42 monoclonal gammopathy of uncertain significance 31.1 TNFSF11 FGFR3 DKK1 B2M
43 parathyroid adenoma 31.1 PTH CALCA ALPP
44 hyperthyroidism 31.1 PTH CALCA BGLAP ACP5
45 beta-thalassemia 31.1 TNFSF11 TNFRSF11B FGF23 BGLAP B2M
46 hypophosphatemic rickets, x-linked dominant 31.0 SOST PTH FGF23 BGLAP ALPL
47 hyperostosis 31.0 TNFRSF11B SOST FGF23 ALPL
48 sclerosteosis 31.0 TNFSF11 SOST RUNX2 PTH DKK1 CTSK
49 exostosis 30.9 SOST RUNX2 EXT2 EXT1 BGLAP
50 glucocorticoid-induced osteoporosis 30.9 TNFSF11 SOST RUNX2 PTH DKK1 CTSK

Graphical network of the top 20 diseases related to Bone Disease:



Diseases related to Bone Disease
Sources

Symptoms & Phenotypes for Bone Disease

About this section

UMLS symptoms related to Bone Disease:


back pain; bone pain; sciatica; muscle cramp

MGI Mouse Phenotypes related to Bone Disease:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 ALPL B2M BGLAP CALCA CD36 CTSK
2 growth/size/body region MP:0005378 10.36 ALPL B2M CD36 CTSK DKK1 EXT1
3 limbs/digits/tail MP:0005371 10.35 ACP5 ALPL CTSK DKK1 EXT1 FGF23
4 cellular MP:0005384 10.25 ALPL B2M BGLAP CD36 CTSK DKK1
5 immune system MP:0005387 10.22 ACP5 ALPL B2M BGLAP CD36 CTSK
6 endocrine/exocrine gland MP:0005379 10.19 ALPL B2M BGLAP CD36 CTSK FGF23
7 skeleton MP:0005390 10.19 ACP5 ALPL BGLAP CALCA CD36 CTSK
8 craniofacial MP:0005382 10.16 ALPL CTSK DKK1 EXT1 FGFR3 PTH
9 digestive/alimentary MP:0005381 10.13 ALPL B2M CD36 CTSK EXT1 FGF23
10 neoplasm MP:0002006 10.09 B2M CALCA DANCR EXT1 FGFR3 TNFRSF11A
11 respiratory system MP:0005388 10.02 ALPL CALCA CTSK DKK1 FGF23 FGFR3
12 reproductive system MP:0005389 10.02 ALPL B2M BGLAP CTSK FGF23 FGFR3
13 hematopoietic system MP:0005397 9.97 ACP5 ALPL B2M BGLAP CD36 CTSK
14 mortality/aging MP:0010768 9.8 ALPL B2M CALCA CD36 DKK1 EXT1
15 integument MP:0010771 9.28 B2M CALCA CD36 FGF23 FGFR3 RUNX2
Sources

Drugs & Therapeutics for Bone Disease

About this section

Drugs for Bone Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 263)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
2
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
3
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
4
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
5
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
6
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
7
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
8
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
9
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
10
Ethinylestradiol Approved Phase 4 57-63-6 5991
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
13
Risedronic acid Approved, Investigational Phase 4 105462-24-6 5245
14
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
15
Tibolone Approved, Investigational Phase 4 5630-53-5 5470 444008
16
Lactulose Approved Phase 4 4618-18-2 11333
17
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005 9568628
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Gliclazide Approved Phase 4 21187-98-4 3475
20 Strontium ranelate Approved, Withdrawn Phase 4 135459-87-9
21
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
22
Sodium fluoride Approved Phase 4 7681-49-4
23
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
24
Desogestrel Approved Phase 4 54024-22-5 40973
25
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
26
Dapagliflozin Approved Phase 4 461432-26-8 9887712
27
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850 155817470
28
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
29
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
31
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
32
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
33
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
34 Analgesics, Opioid Phase 4
35 Sofosbuvir-velpatasvir drug combination Phase 4
36 Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
37 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
38 Emtricitabine tenofovir alafenamide Phase 4
39 Liver Extracts Phase 4
40 Expectorants Phase 4
41 Respiratory System Agents Phase 4
42 Citrate Phase 4
43 Mitogens Phase 4
44 Contraceptives, Oral, Combined Phase 4
45 Contraceptives, Oral Phase 4
46 Contraceptive Agents Phase 4
47
Vitamin D2 Phase 4 3249
48 Ergocalciferols Phase 4
49 Hepcidins Phase 4
50 Olive Phase 4

Interventional clinical trials:

(show top 50) (show all 529)
# Name Status NCT ID Phase Drugs
1 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Unknown status NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
2 The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial Unknown status NCT02704624 Phase 4
3 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant Completed NCT00657852 Phase 4 Disodium pamidronate;Placebo
4 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Completed NCT02999204 Phase 4 Vitamin D3
5 A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients Completed NCT00157690 Phase 4 Alendronate;Placebo
6 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
7 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
8 Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial Completed NCT02214563 Phase 4
9 Regenerative Potential of a Collagen Membrane Associated or Not to Bovine Bone in Class II Furcation Defects - A Randomized Clinical Trial. Completed NCT04450849 Phase 4
10 A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China Completed NCT00774020 Phase 4 Zoledronic acid
11 An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies Completed NCT00740129 Phase 4 Zoledronic Acid
12 Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients: A Prospective, Randomized Placebo-controlled Double Blind Trial Completed NCT02976246 Phase 4
13 Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Completed NCT00772395 Phase 4 Risedronate;Placebo
14 Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation Completed NCT00668200 Phase 4 Reclast (ZOL446, zoledronic acid)
15 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
16 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
17 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
18 A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen. Completed NCT00738257 Phase 4 Pamidronate
19 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Completed NCT00504166 Phase 4 alendronate sodium
20 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
21 A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women Completed NCT00431431 Phase 4 tibolone;raloxifen
22 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
23 A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers Completed NCT00431444 Phase 4 Raloxifene;Zoledronic acid;Placebo oral pills;Placebo intravenous (i.v.) infusion
24 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
25 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4 Zoledronic acid
26 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed NCT00159419 Phase 4 Alendronate;Pamidronate
27 The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Completed NCT00006180 Phase 4 Alendronate
28 Does Treatment of Hypovitaminosis D Increase Calcium Absorption? Completed NCT00581828 Phase 4 Vitamin D
29 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
30 A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women Completed NCT00160264 Phase 4 Lactulose, Vitamin D, Calcium
31 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
32 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
33 Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis Completed NCT00164008 Phase 4 zoledronic acid vs pamidronate
34 Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia Completed NCT00129623 Phase 4 Placebo;ibandronate [Bonviva/Boniva]
35 Primary Mechanisms Underlying the Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis and Bone Metabolism in Young Women Completed NCT02367833 Phase 4 Combined Oral Contraceptive;Transdermal Contraceptive;Contraceptive Vaginal Ring
36 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
37 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
38 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
39 Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids Completed NCT01287533 Phase 4 Ibandronate;Placebo
40 Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I Completed NCT01222026 Phase 4 Strontium Ranelate + Ca/Vitamin-D;Placebo
41 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
42 NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide Completed NCT01153425 Phase 4 Teriparatide;Zoledronic Acid
43 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
44 A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. Completed NCT00365131 Phase 4 Cerezyme (imiglucerase for injection)
45 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Recruiting NCT04087096 Phase 4 Denosumab;Placebo;Zoledronic Acid
46 A Randomized, Double-blind Study of the Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum Vitamin D Levels in Pediatric Patients With Cystic Fibrosis Recruiting NCT05276960 Phase 4 Cholecalciferol Pill
47 Vitamin D Status and Bone Metabolism Status in Children With Congenital Epidermolysis Bullosa Recruiting NCT05141838 Phase 4 Vitamin D
48 Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease Recruiting NCT04522622 Phase 4 Teriparatide
49 Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia: an 1-year Randomized Controlled Trial Recruiting NCT05386784 Phase 4 Raloxifene plus cholecalciferol;Cholecalciferol
50 The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology Active, not recruiting NCT02367846 Phase 4 Combined Oral Contraceptive (COC);Contraceptive Vaginal Ring (CVR)

Search NIH Clinical Center for Bone Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


deferoxamine mesylate

Cochrane evidence based reviews: bone diseases

Sources

Genetic Tests for Bone Disease

About this section
Sources

Anatomical Context for Bone Disease

About this section

Organs/tissues related to Bone Disease:

MalaCards : Bone, Bone Marrow, Kidney, Breast, Prostate, Skin, Spinal Cord
Sources

Publications for Bone Disease

About this section

Articles related to Bone Disease:

(show top 50) (show all 17583)
# Title Authors PMID Year
1
m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. 62 41
36451863 2022
2
Two phenotypes of chronic recurrent multifocal osteomyelitis with different patterns of bone involvement. 41
36456962 2022
3
A randomized, controlled study to assess if allopathic-osteopathic collaboration influences stereotypes, interprofessional readiness, and doctor-patient communication. 41
36455058 2022
4
Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. 53 62
20124286 2010
5
[Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease]. 53 62
20416172 2010
6
The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. 53 62
19660583 2010
7
The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases. 53 62
19931437 2010
8
Osteopontin: an effector and an effect of tumor metastasis. 53 62
20205680 2010
9
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. 53 62
19915614 2010
10
Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. 53 62
19862816 2010
11
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. 53 62
19782692 2010
12
Bone biology and the role of the RANK ligand pathway. 53 62
20128323 2009
13
Serum levels of total-RANKL in multiple myeloma. 53 62
19951882 2009
14
Identification of four novel EXT1 and EXT2 mutations in five Chinese pedigrees with hereditary multiple exostoses. 53 62
19839753 2009
15
Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. 53 62
19587705 2009
16
RUNX2 mutations in Chinese patients with cleidocranial dysplasia. 53 62
19515746 2009
17
Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. 53 62
19201081 2009
18
RANKL inhibition for the management of patients with benign metabolic bone disorders. 53 62
19558335 2009
19
Post-translational Regulation of Runx2 in Bone and Cartilage. 53 62
19734454 2009
20
The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. 53 62
19371798 2009
21
RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. 53 62
19344283 2009
22
Role of RANKL in bone diseases. 53 62
19185505 2009
23
Cathepsin K: a therapeutic target for bone diseases. 53 62
19338743 2009
24
RANK, RANKL and osteoprotegerin in bone biology and disease. 53 62
19468919 2009
25
Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. 53 62
19098682 2009
26
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. 53 62
19016581 2009
27
Clinical applications of RANK-ligand inhibition. 53 62
19356186 2009
28
Action of RANKL and OPG for osteoclastogenesis. 53 62
19191757 2009
29
1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. 53 62
19449179 2009
30
Targeting Src signaling in metastatic bone disease. 53 62
18942061 2009
31
Emerging treatments for postmenopausal osteoporosis - focus on denosumab. 53 62
19554095 2009
32
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. 53 62
18778854 2009
33
[Long-term steroid therapy in children: is adjunct therapy relevant in nephrotic syndrome?]. 53 62
18951767 2008
34
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. 53 62
18991786 2008
35
Vitamin D receptor ligand therapy in chronic kidney disease. 53 62
18826852 2008
36
Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. 53 62
18829534 2008
37
Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. 53 62
18829486 2008
38
RANKL inhibition in the treatment of bone metastases. 53 62
18685421 2008
39
Nutritional rickets and z scores for height in the United Arab Emirates: to D or not to D? 53 62
18937749 2008
40
Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. 53 62
18369625 2008
41
Molecular effects of the tissue-nonspecific alkaline phosphatase gene polymorphism (787T > C) associated with bone mineral density. 53 62
18724009 2008
42
Idiopathic severe elevation of serum alkaline phosphatase following adult renal transplantation: case reports. 53 62
18675129 2008
43
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. 53 62
18312448 2008
44
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. 53 62
18038244 2008
45
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). 53 62
18587716 2008
46
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. 53 62
18057140 2008
47
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. 53 62
18294945 2008
48
A case of lethal hypophosphatasia providing new insights into the perinatal benign form of hypophosphatasia and expression of the ALPL gene. 53 62
17922851 2008
49
RANK ligand as a therapeutic target for bone metastases and multiple myeloma. 53 62
17964729 2008
50
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. 53 62
17728092 2008
Sources

Variations for Bone Disease

About this section

Copy number variations for Bone Disease from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 43764 10 49062854 52062367 Duplication skeletal anomalies
Sources

Expression for Bone Disease

About this section
Search GEO for disease gene expression data for Bone Disease.
Sources

Pathways for Bone Disease

About this section


Pathways directly related to Bone Disease:

# Pathway Source
1 Defective TBXAS1 causes GHDD Reactome 66

Pathways related to Bone Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Vitamin D receptor pathway 74
12.07 TNFSF11 TNFRSF11B PTH FGF23 BGLAP
2
Endochondral ossification 74
Show member pathways
 11.86 RUNX2 PTH FGFR3 ALPL
3
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.71 RUNX2 PTH BGLAP ALPP
4
Overlap between signal transduction pathways contributing to LMNA laminopathies 74
Show member pathways
 11.65 TNFRSF11B RUNX2 CTSK
5
FGF signaling pathway 61
11.4 BGLAP FGF23 FGFR3 RUNX2
6
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.21 TNFSF11 RUNX2 PTH BGLAP
7
Clock-controlled autophagy in bone metabolism 74
11.18 TNFSF11 TNFRSF11B TNFRSF11A SOST RUNX2 PTH
8
Type I collagen synthesis in the context of osteogenesis imperfecta 74
11.17 TNFSF11 TNFRSF11B TNFRSF11A
9
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.15 TNFSF11 TNFRSF11B TNFRSF11A RUNX2 PTH CALCA
10
OSX and miRNAs in tooth development 74
11.08 SOST RUNX2 DKK1 ALPL
12
Proteoglycan biosynthesis 74
10.79 EXT2 EXT1
13
NOTCH1 regulation of endothelial cell calcification 74
10.7 FGFR3 ALPL
14
Autosomal recessive osteopetrosis pathways 74
10.54 TNFSF11 TNFRSF11A
Sources

GO Terms for Bone Disease

About this section

Cellular components related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.03 ALPL B2M BGLAP CALCA CTSK DKK1
2 extracellular space GO:0005615 9.68 TNFSF11 TNFRSF11B SOST PTH FGF23 DKK1

Biological processes related to Bone Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.41 CD36 DKK1 FGF23 PTH RUNX2 TNFSF11
2 response to ethanol GO:0045471 10.21 BGLAP CTSK PTH TNFRSF11A
3 dephosphorylation GO:0016311 10.17 ACP5 ALPL ALPP BGLAP
4 response to insulin GO:0032868 10.13 ALPL BGLAP CTSK TNFRSF11A
5 fibroblast growth factor receptor signaling pathway GO:0008543 10.12 FGFR3 FGF23 EXT1
6 response to mechanical stimulus GO:0009612 10.12 TNFRSF11A SOST BGLAP
7 monocyte chemotaxis GO:0002548 10.1 TNFSF11 TNFRSF11A CALCA
8 bone mineralization GO:0030282 10.06 ALPL BGLAP FGFR3 PTH
9 response to organic cyclic compound GO:0014070 10.05 TNFRSF11A CTSK BGLAP ALPL
10 vasodilation GO:0042311 10.02 EXT2 EXT1 CALCA
11 chondrocyte differentiation GO:0002062 10.02 RUNX2 FGFR3 EXT2 EXT1
12 negative regulation of ossification GO:0030279 10.01 SOST DKK1 CALCA
13 bone morphogenesis GO:0060349 10 FGFR3 EXT1 ACP5
14 response to vitamin D GO:0033280 9.99 PTH BGLAP ALPL
15 phosphate ion homeostasis GO:0055062 9.97 PTH FGF23 ALPL
16 skeletal system development GO:0001501 9.97 TNFRSF11B RUNX2 PTH FGFR3 EXT1 BGLAP
17 endochondral bone growth GO:0003416 9.95 FGFR3 EXT1
18 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process GO:0015014 9.94 EXT2 EXT1
19 endochondral ossification GO:0001958 9.92 ALPL EXT1 FGFR3 RUNX2
20 response to macrophage colony-stimulating factor GO:0036005 9.91 BGLAP ALPL
21 cellular response to zinc ion starvation GO:0034224 9.91 TNFRSF11A CTSK BGLAP
22 calcium ion homeostasis GO:0055074 9.91 TNFSF11 PTH FGF23 ALPL
23 fluid transport GO:0042044 9.89 EXT2 EXT1
24 cellular polysaccharide biosynthetic process GO:0033692 9.88 EXT2 EXT1
25 response to sodium phosphate GO:1904383 9.88 RUNX2 FGF23 ALPL
26 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.86 TNFSF11 TNFRSF11A
27 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.85 TNFSF11 TNFRSF11A
28 endochondral bone morphogenesis GO:0060350 9.8 EXT2 EXT1
29 TNFSF11-mediated signaling pathway GO:0071847 9.73 TNFSF11 TNFRSF11A EXT1
30 bone resorption GO:0045453 9.65 ACP5 CTSK EXT1 PTH TNFSF11
31 ossification GO:0001503 9.5 TNFSF11 TNFRSF11A SOST RUNX2 EXT2 EXT1

Molecular functions related to Bone Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alkaline phosphatase activity GO:0004035 9.56 ALPP ALPL
2 glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity GO:0050508 9.46 EXT2 EXT1
3 N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity GO:0050509 9.26 EXT2 EXT1
4 heparan sulfate N-acetylglucosaminyltransferase activity GO:0042328 8.92 EXT2 EXT1
Sources

Sources for Bone Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....